ACE2 has been reported to inhibit cancer progression in liver hepatocellular carcinoma (LIHC) 17 and pancreatic adenocarcinoma (PAAD) 18, whereas opposite results were observed in kidney renal clear cell carcinoma (KIRC) 19. This evidence concerns the gene ACE2 and pancreatic adenocarcinoma.